Overall, our findings identify miR-665-3p as an endogenous positive regulator of NAFLD via inactivating FNDC5/AMPKα pathway, and inhibiting miR-665-3p may provide novel therapeutic strategies to treat NAFLD. This evidence concerns the gene FNDC5 and metabolic dysfunction-associated steatotic liver disease.